Experience in high-volume online hemodiafiltration.
A longitudinal study of 47 months of follow-up in Ecuador.
DOI:
https://doi.org/10.56867/44Keywords:
Renal Dialysis, Hemodialysis Solutions, Hemodiafiltration, Intermittent Renal Replacement TherapyAbstract
Introduction: High-volume online hemodiafiltration (OL-HDF) offers clinical benefits concerning high-flux hemodialysis (HF-HD) in removing medium molecular weight solutes. The OL-HDF program in Fresenius Clinics Medical Care del Ecuador (FMC-E) began in September 2018. This study aimed to determine the main epidemiological, clinical, and hospitalization parameters in the HDF-OL program and compare them with HD-AF patients.
Methods: The present longitudinal study was carried out in the statistics department of FMC-E from September 3, 2018, to July 30, 2022. Patients receiving renal replacement therapy with >90 days in the hemodialysis program were included. Two groups were formed, the first with HD-AF patients and HDF-OL patients. The variables were demographic, clinical, laboratory, and therapeutic. The source was the EuCLID computer system. The sample was non-probabilistic. Non-inferential and inferential statistics are used.
Results: 3653 patients in HD-AF and 1170 patients in HDF-OL were analyzed. The age of 53.1 years. 5.4 days of hospitalization/patient/year in the HD-AF group and 3.4 in the HDF-OL group ( P <0.01). Hemoglobin 10.9 ± 1.6 gr/dl in HD-AF and 11.1 ± 1.7 gr/dl in HDF-OL ( P<0.001), % transferrin saturation 32.6 ± 15.3% in HD-AF and 31.4 ± 13.5% in HDF-OL ( P =0.02).
Conclusion: Patients undergoing OL-HDF have a better hematological profile, less anemia, and fewer annual hospital requirements.

Downloads
Published
Issue
Section
License
Copyright (c) 2023 Jorge Oswaldo Quinchuela Hidalgo, Gabriela Vanessa Tamayo Albán, Leonor Eugenia Briones Roca (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.